TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 5.01E+3nMAssay Description:Inhibition of human HCN2 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: >3.00E+4nMAssay Description:Inhibition of HCN2 (unknown origin) by patch clamp methodMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: >3.00E+4nMAssay Description:Inhibition of HCN2 (unknown origin) by patch clamp assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibition of human HCN2 expressed in CHO cells by automated patch clamp assayMore data for this Ligand-Target Pair